Navigation Links
Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
Date:11/27/2007

ndidates in clinical development. In addition to iloperidone, Vanda is developing VEC- 162, a compound for the treatment of sleep and mood disorders which is currently in Phase III development for sleep disorders. Vanda's third product candidate in clinical development, VSF-173, is currently in Phase II development for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Note Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A)
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 The ... facilities in New Jersey and even in the U.S. ... that takes inches off of patients’ waists with deep-tissue ... cells in small sections, Vanquish is more inclusive to ... Patients lay comfortably under panels about one inch ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... the planet has been one of the main ... to create a positive impact around the world. ... staffed with top trained executives and trainers deliver ... people worldwide. Vital statistics demonstrate that significant ...
(Date:8/30/2014)... August 30, 2014 Seniors Guide, the comprehensive ... that focus on Alzheimer’s Disease, Dementia, and Memory Loss ... the public of being diagnosed with the Alzheimer’s, inspired Seniors ... “I’ll Be Me”. The movie, out on October 14, ... on his diagnosis of the disease – which inspires a ...
(Date:8/30/2014)... By Randy Dotinga ... -- About one in five patients operated on for broken ... after surgery, a new study finds. Less-educated patients ... times more likely to be "doctor shoppers," said study lead ... Lexington, Ky. Overall, he said, the study suggests that doctors ...
(Date:8/30/2014)... medication commonly used to treat gout, before and ... potential complications from this type of surgery, but ... effects, according to a study published by ... online to coincide with its presentation at the ... after cardiac surgery include postpericardiotomy syndrome (the occurrence ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2
... Philabundance received over $1,200 and 1,000 cans of food ... night, over 300 guests,joined emcee Lori Wilson, co-host of ... for the 2007 Human Resources Department of the Year ... a human resources,placement firm in Voorhees, NJ, was the ...
... 26 In addition to a,$50,000 donation made earlier ... the American Red Cross to aid in the disaster ... actions,they are taking to assist members affected by the ... (EAP): The Blue,Cross EAP is offering free counseling services ...
... study shows , FRIDAY, Oct. 26 (HealthDay News) -- Three ... U.S. researchers report. , Physical activity can also lower their ... says a team that looked at about 200 overweight, inactive ... about healthy nutrition and the benefits of physical activity. In ...
... ... technology-, MADISON, N.J., Oct. 26 ... of diagnostic,testing, information and services, announced today that it has entered ... Diagnostics, SensiTrop(TM) HIV co-receptor tropism test.,Tropism refers to the way a ...
... 1949, to be Awarded Tonight, ATLANTA, Oct. 26 ... health organization -- will present its,highest honor, the Medal ... to the fight against cancer. This year,s winners,who will ... Cancer,Society,s annual meeting in Atlanta are: Matthew L. Myers ...
... have poorer bone density, research shows , FRIDAY, Oct. ... as swimmers, divers and runners, have lower bone density ... bone density levels in these athletes continued to decrease, ... fractures, other bone injuries, and even osteoporosis, said a ...
Cached Medicine News:Health News:SIEMENS, AlliedBarton, Methodist Hospital, and Family Planning Council Win Human Resources Department of the Year Awards 2Health News:Blue Cross of California Reaches Out to Members Impacted by Southern California Fires 2Health News:Exercise Helps Overweight Youngsters Learn 2Health News:Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics 2Health News:Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics 3Health News:Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics 4Health News:American Cancer Society to Present Highest Honor to Matthew L. Myers, Douglas R. Lowy, and Mark Schiffman for Outstanding Contributions to Cancer Fight 2Health News:American Cancer Society to Present Highest Honor to Matthew L. Myers, Douglas R. Lowy, and Mark Schiffman for Outstanding Contributions to Cancer Fight 3Health News:American Cancer Society to Present Highest Honor to Matthew L. Myers, Douglas R. Lowy, and Mark Schiffman for Outstanding Contributions to Cancer Fight 4Health News:Some Female Athletes Risking Weaker Bones 2
Shielding's Fast Wrap Apron offers both comfort and ease of wearing. Adjustable back shoulder strap keeps apron snug. No ties or buckles....
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
Shielding's Economy Coat Apron offers the same features as our Standard Coat Apron with an open back allowing for freedom of movement, maximum flexibility and increased comfort....
Upper arm protection...
Medicine Products: